UBS strongly resets Lilly stock target
Eli Lilly (LLY) has seen a lot of bullish calls from Wall Street in July. Guggenheim, Truist, Bank…
ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free…
UBS Upgrades Biogen to Buy With a $225 Target: Are the Next 12 Months a Pipeline Catalyst Parade?
Biogen (BIIB) stock got an upgrade to Buy from UBS with a $225 price target, citing upcoming BIIB080…